{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T17:11:21Z","timestamp":1771693881625,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Pillars"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.obpill.2026.100246","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T16:19:15Z","timestamp":1767802755000},"page":"100246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Obesity medications and acquired hypothalamic obesity in adults: A two-case experience"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6148-5978","authenticated-orcid":false,"given":"Henry","family":"Lang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1973-1009","authenticated-orcid":false,"given":"Madisen F.","family":"Dorand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahnooor","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7985-8882","authenticated-orcid":false,"given":"Jesse R.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.obpill.2026.100246_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.appet.2022.106022","article-title":"A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus","volume":"174","author":"Smith","year":"2022","journal-title":"Appetite"},{"key":"10.1016\/j.obpill.2026.100246_bib2","first-page":"73","article-title":"263-OR: effects of tirzepatide on central reward and appetite circuits in the brain","author":"Carmichael","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.obpill.2026.100246_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2021.793004","article-title":"GLP-1 suppresses feeding behaviors and modulates neuronal electrophysiological properties in multiple brain regions","volume":"14","author":"Chen","year":"2021","journal-title":"Front Mol Neurosci"},{"issue":"13","key":"10.1016\/j.obpill.2026.100246_bib4","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2116506119","article-title":"Structural determinants of dual incretin receptor agonism by tirzepatide","volume":"119","author":"Sun","year":"2022","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"10.1016\/j.obpill.2026.100246_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.obpill.2026.100246_bib6","doi-asserted-by":"crossref","first-page":"802","DOI":"10.4093\/dmj.2020.0258","article-title":"Comprehensive review of current and upcoming anti-obesity drugs","volume":"44","author":"Son","year":"2020","journal-title":"Diabetes Metab J"},{"issue":"1","key":"10.1016\/j.obpill.2026.100246_bib7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1152\/jn.00012.2015","article-title":"D1 and D2 antagonists reverse the effects of appetite suppressants on weight loss, food intake, locomotion, and rebalance spiking inhibition in the rat NAc shell","volume":"114","author":"Kalyanasundar","year":"2015","journal-title":"J Neurophysiol"},{"issue":"2","key":"10.1016\/j.obpill.2026.100246_bib8","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/sj.ijo.0801889","article-title":"Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials","volume":"26","author":"Haddock","year":"2002","journal-title":"Int J Obes"},{"issue":"2","key":"10.1016\/j.obpill.2026.100246_bib9","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely Obese adults: a randomized controlled trial (EQUIP)","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity"},{"issue":"9774","key":"10.1016\/j.obpill.2026.100246_bib10","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.obpill.2026.100246_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13439","article-title":"Hypothalamic obesity: epidemiology in rare sellar\/suprasellar tumors\u2014A German claims database analysis","volume":"36","author":"Witte","year":"2024","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.obpill.2026.100246_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2024.171271","article-title":"Tirzepatide shows neuroprotective effects via regulating brain glucose metabolism in APP\/PS1 mice","volume":"179","author":"Yang","year":"2024","journal-title":"Peptides"},{"issue":"3","key":"10.1016\/j.obpill.2026.100246_bib13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1210\/endrev\/bnad033","article-title":"Appetite- and weight-regulating neuroendocrine circuitry in hypothalamic obesity","volume":"45","author":"Gan","year":"2024","journal-title":"Endocr Rev"},{"issue":"11","key":"10.1016\/j.obpill.2026.100246_bib14","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1210\/jc.2002-021797","article-title":"Obesity in patients with craniopharyngioma: assessment of food intake and movement counts indicating physical activity","volume":"88","author":"Harz","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.obpill.2026.100246_bib15","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1210\/jc.2003-031751","article-title":"Longitudinal study on growth and body mass index before and after diagnosis of childhood craniopharyngioma","volume":"89","author":"M\u00fcller","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.obpill.2026.100246_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1297\/cpe.16.1","article-title":"Prevalence of obesity, hyperlipemia and insulin resistance in children with suprasellar brain tumors","volume":"16","author":"Adachi","year":"2007","journal-title":"Clin Pediatr Endocrinol"},{"issue":"4","key":"10.1016\/j.obpill.2026.100246_bib17","first-page":"1235","article-title":"Pathophysiology and individualized treatment of hypothalamic obesity following craniopharyngioma and other suprasellar tumors: a systematic review","volume":"40","author":"van Iersel","year":"2019","journal-title":"Endocr Rev"},{"issue":"3","key":"10.1016\/j.obpill.2026.100246_bib18","first-page":"222","article-title":"Hypothalamic obesity in patients with craniopharyngioma: mechanisms, diagnosis, and treatment","volume":"111","author":"Roth","year":"2021","journal-title":"Neuroendocrinology"},{"issue":"1","key":"10.1016\/j.obpill.2026.100246_bib19","first-page":"45","article-title":"Genetic and acquired forms of hypothalamic obesity: mechanistic overlap and emerging treatment targets","volume":"12","author":"Barlow","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.obpill.2026.100246_bib20","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s11060-022-04116-2","article-title":"Physical function, body mass index, and fitness outcomes in children, adolescents, and emerging adults with craniopharyngioma from proton therapy through five years of follow-up","volume":"159","author":"Partin","year":"2022","journal-title":"J Neuro Oncol"},{"key":"10.1016\/j.obpill.2026.100246_bib21","article-title":"Metabolic syndrome as a common comorbidity in adults with hypothalamic dysfunction","volume":"13","author":"Xu","year":"2022","journal-title":"Front Endocrinol [Internet]"},{"issue":"5","key":"10.1016\/j.obpill.2026.100246_bib22","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1210\/clinem\/dgac678","article-title":"Approach to the patient with hypothalamic obesity","volume":"108","author":"Shoemaker","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.obpill.2026.100246_bib23","series-title":"A phase 2, open-label 20-Week study to evaluate the safety and efficacy of setmelanotide in subjects with hypothalamic obesity [Internet]","year":"2025"},{"key":"10.1016\/j.obpill.2026.100246_bib24","series-title":"Phentermine\/topiramate in children, adolescents, and young adults with hypothalamic obesity: a pilot and feasibility study [Internet]","author":"Roth","year":"2025"},{"issue":"4","key":"10.1016\/j.obpill.2026.100246_bib25","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cmet.2016.02.005","article-title":"Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity","volume":"23","author":"Magkos","year":"2016","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.obpill.2026.100246_bib26","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/dom.14224","article-title":"A phase 3 randomized clinical trial using a once\u2010weekly glucagon\u2010like peptide\u20101 receptor agonist in adolescents and young adults with hypothalamic obesity","volume":"23","author":"Roth","year":"2021","journal-title":"Diabetes Obes Metabol"},{"issue":"5","key":"10.1016\/j.obpill.2026.100246_bib27","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1530\/EJE-12-0997","article-title":"GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases","volume":"168","author":"Zoicas","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.obpill.2026.100246_bib28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/ejendo\/lvae024","article-title":"Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial","volume":"190","author":"Gatta-Cherifi","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.obpill.2026.100246_bib38","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s11102-024-01429-5","article-title":"Semaglutide treatment of hypothalamic obesity: a real-life data study","volume":"27","author":"Svendstrup","year":"2024","journal-title":"Pituitary"},{"key":"10.1016\/j.obpill.2026.100246_bib29","article-title":"Failure of GLP-1 agonist therapy to improve weight in a 3-year-old patient with tumor-related obesity","volume":"2025","author":"Petlansky","year":"2025","journal-title":"Case Rep Pediatr"},{"issue":"6","key":"10.1016\/j.obpill.2026.100246_bib30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11102-025-01602-4","article-title":"Craniopharyngioma \u2013 what's next","volume":"28","author":"M\u00fcller","year":"2025","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.obpill.2026.100246_bib31","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/dom.70216","article-title":"Effectiveness and safety of GLP-1 receptor agonists in craniopharyngioma patients with obesity: a multicentre real-world study","volume":"28","author":"Lambert","year":"2026","journal-title":"Diabetes Obes Metabol"},{"issue":"5","key":"10.1016\/j.obpill.2026.100246_bib32","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11102-025-01564-7","article-title":"Semaglutide treatment in hypothalamic obesity: two-year outcomes on body composition, appetite, and quality of life","volume":"28","author":"Gjersdal","year":"2025","journal-title":"Pituitary"},{"issue":"5","key":"10.1016\/j.obpill.2026.100246_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2025.102018","article-title":"The management of hypothalamic obesity in craniopharyngioma","volume":"39","author":"Dimitri","year":"2025","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"issue":"3","key":"10.1016\/j.obpill.2026.100246_bib34","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/cen.15262","article-title":"The efficacy of semaglutide on hypothalamic obesity caused by craniopharyngioma surgery","volume":"103","author":"Wang","year":"2025","journal-title":"Clin Endocrinol"},{"issue":"1","key":"10.1016\/j.obpill.2026.100246_bib35","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae200","article-title":"Treatment of hypothalamic obesity with GLP-1 analogs","volume":"9","author":"Dimitri","year":"2024","journal-title":"J Endocr Soc"},{"issue":"3","key":"10.1016\/j.obpill.2026.100246_bib36","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/jdi.14372","article-title":"Glucagon-like peptide-1 receptor agonists suggest novel therapeutic options for hypothalamic obesity","volume":"16","author":"Ma","year":"2025","journal-title":"J Diabetes Investig"},{"issue":"5","key":"10.1016\/j.obpill.2026.100246_bib37","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s11102-024-01443-7","article-title":"Is semaglutide a target therapy for acquired hypothalamic obesity?","volume":"27","author":"Prodam","year":"2024","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.obpill.2026.100246_bib39","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12642","article-title":"The role of glucagon-like peptide-1 receptor agonists for weight control in individuals with acquired hypothalamic obesity: a systematic review","volume":"14","author":"Ng","year":"2024","journal-title":"Clin Obes"},{"issue":"3","key":"10.1016\/j.obpill.2026.100246_bib40","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41366-021-01043-6","article-title":"Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist","volume":"46","author":"Shoemaker","year":"2022","journal-title":"Int J Obes"},{"key":"10.1016\/j.obpill.2026.100246_bib41","article-title":"Evaluating the effectiveness and underlying mechanisms of incretin-based treatments for hypothalamic obesity: a narrative review","volume":"10","author":"Chartoumpekis","year":"2024","journal-title":"Obes Pillars"},{"issue":"2","key":"10.1016\/j.obpill.2026.100246_bib42","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/dom.14224","article-title":"A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity","volume":"23","author":"Roth","year":"2021","journal-title":"Diabetes Obes Metabol"},{"issue":"4","key":"10.1016\/j.obpill.2026.100246_bib43","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1365-2265.2012.04368.x","article-title":"A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus","volume":"77","author":"Thondam","year":"2012","journal-title":"Clin Endocrinol"},{"issue":"S2","key":"10.1016\/j.obpill.2026.100246_bib44","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/dom.15530","article-title":"Acquired hypothalamic obesity: a clinical overview and update","volume":"26","author":"Roth","year":"2024","journal-title":"Diabetes Obes Metabol"},{"issue":"10","key":"10.1016\/j.obpill.2026.100246_bib45","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"J Clin Investig"},{"issue":"5","key":"10.1016\/j.obpill.2026.100246_bib46","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.cmet.2019.07.013","article-title":"Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake","volume":"30","author":"Adriaenssens","year":"2019","journal-title":"Cell Metab"},{"issue":"12","key":"10.1016\/j.obpill.2026.100246_bib47","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/s42255-023-00931-7","article-title":"Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice","volume":"5","author":"Liskiewicz","year":"2023","journal-title":"Nat Metab"},{"issue":"3","key":"10.1016\/j.obpill.2026.100246_bib48","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/oby.21387","article-title":"Effects of liraglutide in hypothalamic arcuate nucleus of obese mice","volume":"24","author":"Barreto-Vianna","year":"2016","journal-title":"Obesity"},{"issue":"2","key":"10.1016\/j.obpill.2026.100246_bib49","doi-asserted-by":"crossref","first-page":"H244","DOI":"10.1152\/ajpheart.00096.2015","article-title":"Should the sympathetic nervous system be a target to improve cardiometabolic risk in obesity?","volume":"309","author":"Lambert","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"10.1016\/j.obpill.2026.100246_bib50","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s13679-023-00546-9","article-title":"Phentermine in the modern era of obesity pharmacotherapy: does it still have a role in treatment?","volume":"13","author":"Lewis","year":"2024","journal-title":"Curr Obes Rep"},{"issue":"2","key":"10.1016\/j.obpill.2026.100246_bib51","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1210\/endrev\/bnac015","article-title":"Brown adipose tissue\u2014A translational perspective","volume":"44","author":"Carpentier","year":"2023","journal-title":"Endocr Rev"},{"issue":"9","key":"10.1016\/j.obpill.2026.100246_bib52","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1210\/en.2012-1272","article-title":"Topiramate treatment improves hypothalamic insulin and leptin signaling and action and reduces obesity in mice","volume":"153","author":"Caricilli","year":"2012","journal-title":"Endocrinology"}],"container-title":["Obesity Pillars"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T16:46:04Z","timestamp":1771692364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667368126000021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":52,"alternative-id":["S2667368126000021"],"URL":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100246","relation":{},"ISSN":["2667-3681"],"issn-type":[{"value":"2667-3681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obesity medications and acquired hypothalamic obesity in adults: A two-case experience","name":"articletitle","label":"Article Title"},{"value":"Obesity Pillars","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100246","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Obesity Medicine Association.","name":"copyright","label":"Copyright"}],"article-number":"100246"}}